A new clinical model for terminal idiopathic pulmonary fibrosis that allows patients to receive treatment at home has increased patient satisfaction, decreased hospital deaths, led to better symptom management, and lowered healthcare costs.
A patient with idiopathic pulmonary fibrosis, enrolled in the ZEPHYRUS Phase 3 clinical study, has been dosed with FibroGen’s investigational therapy pamrevlumab, the company announced.
A new study reinforces that lack of tissue oxygenation, also known as hypoxia, is involved in the development and progression of idiopathic pulmonary fibrosis.
The Assistance Fund, an independent and charitable foundation, announced that it has launched a new copay assistance program to support people with idiopathic pulmonary fibrosis.
